

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : De Sauvage et al.

Group Art Unit 1647

Appl. No. : 09/272,835

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

Filed : March 19, 1999

For : GFRALPHA3 AND ITS USES

November 8, 2001

(Date)

Examiner : Hayes, R.

Ginger R. Dreger, Reg. No. 33,055

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed on October 15, 2001 (Paper No. 18), setting a one month term, Applicants hereby request the entry of the substitute "Sequence Listing" submitted concurrently herewith into the specification, starting on a new page, immediately following the claims, and of the following amendments to the specification. The present substitute Sequence Listing serves to replace the Sequence Listing filed on August 2, 2001.

In the Specification:

Please replace the paragraph beginning at page 3, line 16, with the following rewritten paragraph:

--In one embodiment, the invention provides an isolated nucleic acid molecule having at least about 65% sequence identity to (a) a nucleic acid sequence encoding a GFR α 3 polypeptide comprising the sequence of amino acids 27 to 400 of SEQ ID NO: 15, amino acids 27 to 369 of SEQ ID NO: 17 or amino acids 27 to 374 of SEQ ID NO: 5 or (b) the complement of the nucleic

ger, Reg. No. 33,055

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900